National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

modified vaccinia Ankara (Bavarian Nordic)-HER2 vaccine
A cancer vaccine consisting of a proprietary, recombinant modified vaccinia Ankara (MVA) viral vector encoding an epitope of human epidermal growth factor receptor 2 (HER2) with potential antineoplastic activity. Upon administration, modified vaccinia Ankara (Bavarian Nordic)-HER2 vaccine may stimulate the host immune system to mount humoral and cytotoxic T lymphocyte responses against HER2-expressing tumor cells, resulting in tumor cell lysis. HER2, also known as ErbB-2, is a tyrosine kinase growth factor receptor and a member of the epidermal growth factor receptor family; it plays a significant role in the pathogenesis of some breast cancers. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonym:MVA-BN-HER2 vaccine
Foreign brand name:MVA-BN Breast



Previous:Mobec, Mobic, Mobicox, Mobist, modafinil
Next:Modrastane, molybdenum, mometasone furoate, monobenzone, monoclonal antibody 105AD7 anti-idiotype vaccine

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov